https://orcid.org/0000-0001-7192-2393
![Sample our Engineering & Technology journals, sign in here to start your access, latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5933/TOC-Subject-Sample-2021-Engineering-Tech.jpg"})
Abstract
Aim: To develop hyaluronic acid (HA)-coated poly-lactic-co-glycolic acid (PLGA)-polysarcosine (PSAR) coupled sorafenib tosylate (SF) polymeric nanoparticles for targeted colon cancer therapy. Materials & methods: PLGA–PSAR shells were encapsulated with SF via nanoprecipitation. Interactions were examined with transmission electron microscopy, revealing formulation component interactions. Results: The optimized HA-coated polymeric nanoparticles (238.8 nm, -6.1 mV, 68.361% entrapment) displayed enhanced controlled release of SF. These formulations showed superior cytotoxicity against HCT116 cell lines compared with free drug (p < 0.05). In vivo tests on male albino Wistar rats demonstrated improved pharmacokinetics, targeting and biocompatibility. HA-coated PLGA–PSAR-coupled SF polymeric nanoparticles hold potential for effective colorectal therapy. Conclusion: Colon cancer may be precisely targeted by HA-coated PLGA–PSA-coupled SF polymeric nanoparticles.
Graphical abstract
Supplementary data
To view the supplementary data that accompany this paper please visit the journal website at: www.tandfonline.com/doi/suppl/10.2217/nnm-2023-0145
Author contributions
N Phatak: writing – original draft. S Bhattacharya: conceptualization, validation of data, supervision, writing, visualization, communication with the journal. D Shah: pharmacological studies, data collection, conceptualization. L Manthalkar: conceptualization, writing. P Sreelaya: conceptualization, writing. A Jain: conceptualization, writing.
Financial disclosure
The authors have no financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Competing interests disclosure
The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Writing disclosure
No writing assistance was utilized in the production of this manuscript.
Ethical conduct of research
The authors state that he pharmacokinetic and biodistribution activity was conducted in accordance with ethical guidelines approved by the Institutional Ethical Committee (CPCSEA) at a recognized laboratory animal facility in School of Pharmacy & Technology Management, Shirpur, India (SPTM/2023/IAEC/25). The authors state that the principles outlined in the declaration of Helsinki were followed in animal experimental investigations.
Acknowledgments
This initiative would not have been possible without the help and support of RS Gaud, Pharma Section Director, SVKM’s NMIMS Deemed-to-Be University, Mumbai, India. The authors thank DIYA LAB, Mumbai, India, for its logistical and analytical assistance throughout the development of this project. The authors also thank Aakaar Biotechnologies Pvt. Ltd, Lucknow, Uttar Pradesh 226031, India, for conducting entire in vitro anticancer activity. The authors also express gratitude to Deshpande Laboratories (DL) Pvt. Ltd, Bhopal, MP, India, for helping in the in vivo animal studies. The authors acknowledge the financial support received from the CRS Project – UGC-DAE Consortium for Scientific Research [2021/CRS/48/40/594], and extend their gratitude to G Pramanik, Scientist-D, UGC-DAE Consortium for Scientific Research, Kolkata Centre, for his valuable assistance throughout the project.